Family Guy S14E02 REAL HDTV x264-KILLERS[ettv] | Papystreaming | Money Can Suck My Cock

Development of immunization trials against Pasteurella multocida

Development of immunization trials against Pasteurella multocida

Vaccine 32 (2014) 909–917 Contents lists available at ScienceDirect Vaccine journal homepage: Review Development o...

2MB Sizes 0 Downloads 0 Views

Vaccine 32 (2014) 909–917

Contents lists available at ScienceDirect

Vaccine journal homepage:


Development of immunization trials against Pasteurella multocida Tarek A. Ahmad a,∗ , Samar S. Rammah b , Salah A. Sheweita b , Medhat Haroun b , Laila H. El-Sayed c a b c

Scientific Support and Projects Section, Bibliotheca Alexandrina, Alexandria, Egypt Biotechnology Department, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt Immunology Department, Medical Researches Institute, Alexandria University, Alexandria, Egypt

a r t i c l e

i n f o

Article history: Received 23 September 2013 Received in revised form 4 November 2013 Accepted 18 November 2013 Available online 2 December 2013 Keywords: Pasteurellosis Pasteurella multocida Vaccine Immunotherapy

a b s t r a c t Pasteurellosis is one of the most important respiratory diseases facing economically valuable farm animals such as poultry, rabbit, cattle, goats and pigs. It causes severe economic loss due to its symptoms that range from primary local infection to fatal septicemia. Pasteurella multocida is the responsible pathogen for this contagious disease. Chemotherapeutic treatment of Pasteurella is expensive, lengthy, and ineffective due to the increasing antibiotics resistance of the bacterium, as well as its toxicity to human consumers. Though, biosecurity measures played a role in diminishing the spread of the pathogen, the immunization methods were always the most potent preventive measures. Since the early 1950s, several trials for constructing and formulating effective vaccines were followed. This up-to-date review classifies and documents such trials. A section is devoted to discussing each group benefits and defects. © 2013 Elsevier Ltd. All rights reserved.

1. Introduction Farm animals are very important to our daily lives. They are the main source for many of our basic needs such as proteins, vitamins, dairy products, eggs and also clothes. Animals, like people, suffer from diseases and need proper care from veterinarians. Animal infections cause severe disease outbreaks especially those caused by microbes that spread rapidly between domesticated animals. Although antibiotics are the main means to control such microbial incidences, their drawbacks highlight the need to find new potent ways to manage infections among animals [1]. Furthermore, the remains of those antibiotics in the animal products indirectly affect human health. The primary control of the infectious diseases of domesticated animals depends on good biosecurity. Vaccines are used simultaneously to prevent clinical symptoms of the diseases before infection and to control an infection at the population level. Veterinary vaccines play a major role in improving the health and welfare of companion animals and preventing animal-to-human transmission from both domesticated and wild animals [2]. Respiratory infections cause significant economic loss in sheep, goats, rabbits, poultry, and other farm animals. They often result from adverse physiological stress, or viral and bacterial infection interactions. Those infections cause high mortality rates that may reach 50% in infected animals [3]. One of the major causes in

∗ Corresponding author. Tel.: +20 1001701579. E-mail address: [email protected] (T.A. Ahmad). 0264-410X/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.

the respiratory infections of farm animals is Pasteurella multocida. The disease causes pneumonia, genital infections, abscesses, and septicemia, and hence induces shortage in production and high mortality rates, therefore considerable economic loss. It appears in 20% of the entire stock of rabbits during summer, this increases in September and October to reach 50–60%, and then decreases gradually to enroll another rise in March and April. It reaches the lowest level during July and August [4,5]. However, in lambs it induces high mortality rates after 10–12 h of birth and manifests its outbreaks in sheep older than 3 months in May, June, and July [6]. This disease is responsible for 30% of the total cattle deaths worldwide [7,8] and losses of one billion dollars annually in beef cattle industry in North America alone [9]. Moreover enormous economic losses of pigs [10–12], poultry [13–15], and Chimpanzees [16] are due to P. multocida. Pasteurella species used to be classified as a member of genus Mannheimia. P. multocida is a non motile capsulated Gram-negative coccobacillary to rod shaped facultative anaerobic bacterium [17]. P. multocida serotyping is based on CPS, where the most pathogenic types are A1, A3, A1,3, A4, B2, and D1 [18–21]. It colonizes the nasopharynx, the respiratory tract and gastrointestinal tract of many animals and induces a disease called pasteurellosis. Under stress conditions, the commensal P. multocida becomes a pathogen by overwhelming the immune system of the host, proliferating in the nasopharynx and spreading to lungs [22]. It is an opportunistic pathogen responsible for fowl cholera (FC) of poultry, hemorrhagic septicemia (HS) of buffalo, pneumonia of lambs and goats, respiratory atrophic rhinitis of swine (AR) and purulent rhinitis (snuffles) of rabbits [23]. Although humans can be infected by handling carrier


T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

animals, it is a rare cause of adult meningititis. However P. multocida is the major cause of soft tissue infection after animal bites, especially those due to cats [24]. Pasteurellosis is a serious and highly contagious disease affecting domestic animals because its control methods are complex and treatment is expensive, lengthy and ineffective [5]. The use of antibiotics is a successful method to control Pasteurella infection. However, the microbial resistance limited antibiotics potency and about 80.5% of P. multocida showed to be resistant [25–27]. Scientist’s efforts were directed toward introducing new antibiotics to control resistant mutants, but unfortunately, pharmaceutical companies produced only few antibiotics specifically for Gram-negative bacteria [28], and therefore prevention was introduced as a successful tool for control [5,26,27,29]. 2. Prevention and immunotherapy The urgent need for a safe and potent control system led the scientists to use biosecurity protocols for the disease prevention. Although infection control methods proved to be a good way to minimize the infection spread and to reduce losses, these methods were not sufficiently effective to manage the spread of the disease [30]. Immunotherapies have made radical changes in the field of animal protection and treatment against infectious diseases. Immunoenhancers are products that enhance a number of non-specific natural killer cells or mechanisms, and hence the immune response increases. Cell-mediated immune response was achieved in chickens by the macrophage activating factor from T-lymphocytes [31]. Some components in the attenuated avirulent P. multocida [32] and the bacterium itself [33] simultaneously increased the phagocytic activity in the respiratory tract of chickens. But to the best of the authors’ knowledge no specialized products were used to increase the non-specific immune response against P. multocida. The following paragraphs classify the specific immunotherapy trials. 2.1. Passive immunization Several studies between 1975 and 1990 proved that the antisera raised against Clemson University avirulent P. multocida vaccine (CU vaccine), potassium thiocyanate extract of Pasteurella, and heat killed bacterium conferred protection to baby turkeys, rabbits and mice; respectively [34–36]. Studies in 1991, showed that the monoclonal antibodies (mAbs) raised against outer membrane proteins (OMP) of P. multocida were effective to immunize rabbits and mice against pasteurellosis, and to inhibit the bacterium proliferation in lungs [37–39]. Further studies starting from 1997 to 2007, proved that ammonium sulphate perceptible protein fractions (PSAP) of P. multocida [40], outer membrane protein H (OmpH) [41], Omp87 [42], and mixture of OMPs [43] of P. multocida proved to be effective against homologous infection by P. multocida in mice, rabbits and bovine. However, the antiserum against the bacterial glycoprotein provided cross-protection to chickens against heterologous challenge by different serovars [13]. Although, the protection potency was lacking or partial when mAbs were raised against lipopolysaccharide (LPS), in mice challenged with homologous pathogen [39,44], the polyclonal anti-idiotype antibodies against the protein that mimic the P. multocida LPS, protected mice against P. multocida infection [45]. 2.2. Active immunization Vaccination is the most effective and economic method to confer protection to animals against Pasteurella and minimize the symptoms of pasteurellosis [46]. The following paragraphs trace the development of those trials to construct effective vaccines against

Pasteurella spp. However to the best of the authors’ knowledge some preparations missed the clear description to be classified such as, the monovalent Pasteurella vaccine [47], the emulsified vaccine against swine pasteurellosis [48], the polyvalent oil-adjuvanted vaccine against birds pasteurellosis [49], the formulation prepared to prevent Pasteurella in cattle [50], the faction vaccine [51], and the subunit vaccine [52]. 2.2.1. Whole cell vaccines These vaccines are called the first generation vaccines. They can be used as a whole inactivated/killed, live attenuated or lysate bacterial cells to elicit the desired immune response. Killed vaccines. The inactivated vaccines (bacterins) are prepared from Pasteurella killed by various ways such as heat, drying, formalin, phenol, or sodium azide. Heddleston and Hall [14] proved the high homologous potency due to the immunization of chickens using formalin-killed P. multocida, and examined the efficacy of the bacterial lysate in 1968 [53]. Starting in 1972 and for five years a series of experiments were performed by Heddleston and Rebers [54] on the formalin-killed host-passaged in vivo-propagated P. multocida. Although, they proved that the produced bacterin induce high cross-immunity against the bacterial challenge, the immunity was host specific [55] and was half of that conferred by the standard bacterium [56]. Later on the safety [57], and efficacy of the bacterium were tested in lambs [58]. However, in 2004, Dowling et al. [59] could not prove that lung exposure to formalin-killed P. multocida vaccine induced protective immunity in calves against homologous challenge. Emulsified water-in-oil bacterins prepared from formalin-killed P. multocida protected poultry from homologous challenge [60], reduced the number of infected turkeys from the avirulent vaccine [61], and induced only a systemic antibody titer in turkeys [62]. Scientists at the faculty of veterinary medicine in Belgium continued the trials on formalin-killed oil-adjuvanted Pasteurella vaccine (OAV) between 1980 and 1987. They proved that the preparation gave low immune response [63], and resulted in local tissue irritation and lession in mice [64]. However, other scientists demonstrated its potency in ducks [65], calves [66,67], and mice when heat killed Pasteurella is used [36]. The heat killed OAV showed reduced local reaction in poultry [68], and conferred 60% cross-protection to mice against homologous challenge [69]. Although it was confirmed that the degree of protection depends mainly on the number of doses [70,71], Gunawardana et al. [72] applied immunoblotting to study the advantages that adjuvants add to bacterin. Several studies were performed to evaluate the potency of different adjuvants [73]. The formalin-killed P. multocida was formulated with the Egyptian propolis to immunize rabbits against P. multocida infection and proved some improvement in the efficacy of the vaccine [74]. Moreover, OAV formulated with saponin provided strong humoral and cellular immune response against hemorrhagic septicemia in mice and calves [75]. The multiple emulsion vaccine (MEV), which was prepared by re-emulsifying of OAV with an equal volume of Tween 80, was a successful formulation for buffaloes protection against hemorrhagic septicemia over 6 month [7], and extended for one year in animals such as rabbits and calves [76,77]. Vaccination of calves with P. multocida bacterin formulated with toxoid conferred high immune response [78]. Although, buffaloes vaccinated with alumprecipitated vaccine a protection of 6 months, those vaccinated by OAV and double emulsion vaccines had a long-lasting protection that reached 12 months against hemorrhagic septicemia [7,79,80]. Moreover, cross-protection against heterologous challenge was achieved in buffalo immunized with OAV of P. multocida serotype B:2,5 [81]. Another approach for improving Pasteurella killed bacterin is the preparation of multivalent vaccines. Bivalent vaccines

T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

which consist of two serotypes of Pasteurella were effective in protecting rabbits from pasteurellosis [82], pentavalent vaccines decreased symptoms in calves [83], but not birds’ fowl cholera [44]. Although the bacterin of iron-depleted Pasteurella failed to induce cross-protection in poultry or rabbits [84,85], the full bacterin succeeded [86]. Several research projects failed to prove the effect of preparing vaccines for Pasteurella grown under different conditions [87]. Two years later in India, it was proven that ironinactivated P. multocida bacterin formulated with the bacterial DNA enhanced the protective potency of the poultry against fowl cholera [88]. Vaccination with bacterins has many disadvantages, as it lacks the ability to raise cross serotype protection, results in ineffective and short immunity, and immunized animals still suffer disease outbreak [23,74]. Moreover, bacterin results in inflammation at the site of injection [89]. Live attenuated vaccines. Avirulent strains P. multocida were frequently used to formulate live attenuated vaccines against pasteurellosis. P. multocida serotypes A3 (P1059) [42,90], B3, and B4. Although they provided high protection to cattle for 13 months [76,91,92], they lacked the maternal potency [93]. The A/D strains elicited a potent response against homologous challenge in mice [94]. Moreover, mice showed tolerance when immunized with Pasteurella of pig origin [95]. P. multocida serotype B:2 grown under iron-restricted conditions offered a high protective potency against homologous infection in cattle and rabbits [96]. The acapsular serotype of P. multocida induced homologous and heterologous protection to mice and chicks [61,97,98]. The induction of mutations by mutagenic substances such as N-methyl-N -nitroN-nitrosoguanidine was a promising strategy to produce potent attenuated vaccines. Avirulent mutant strains of P. multocida M8283 [99] and M3G [100,101] offered turkeys high cross-protection against fowl cholera homologous and heterologous challenges when administered into drinking water. The use of the avirulent Clemson University strain of P. multocida (CU vaccine) in attenuated vaccines was extensively studied. High protective immune response was induced when turkeys and chickens were immunized with live CU vaccine [102–105]. In 1978, unlike the bacterin, the oral vaccination of turkeys with live CU vaccine showed to induce protective cellular and humoral responses in the respiratory organs against fowl cholera for four to six weeks without any adverse effects [62,106,107]. The survival rate of turkey hens that received the live CU vaccine reached 92% without any side effects [107], and that of chickens varied between 95 and 97.5% [108]. Therefore, Bierer and Eleazer [109] and later Heddleston [110] advised the use of live vaccine in the drinking water of turkeys to prevent fowl cholera. In 1977, Bierer [111,112] proved that increasing the concentration of CU vaccine administered in drinking water increases the degree of the vaccine’s protection level in turkeys. In 1977 it was proved that the efficiency of the CU vaccine increased by cofeeding the turkeys by sulfadimethoxine and ormetoprim [113] or lavamisole, the broad-spectrum anthelmintic [114]. Later on in 1980, it was proven that the number of immunizations was a distinct factor in increasing the efficiency of CU vaccine. Immunization of chickens with avirulent CU strain of P. multocida two or three times gave higher protection than one-time vaccination [115]. The route of immunization as well affected the efficiency of immunization. Oral vaccination of turkey breeder hens and broiler chickens with CU vaccine via both mouth and wing-web stick routes induced high immune response that lasted for 25–30 weeks with few adverse effects, but immunization of turkeys with high dose of the vaccine through wing-web route led to severe wing lesions [116,117]. Similar duration of protection was attained by subcutaneous vaccination of chickens [118], and oral vaccination


in turkeys [119]. The factors of the bird’s age and type affected the potency. Although the potency of live CU vaccine was positively proved in turkeys and breeder-hens [120], chickens were not efficiently protected from fowl cholera [71], and when broiler-type chickens were immunized with live CU vaccine, antibody titer and immune response increased when vaccinated chickens increased in age [121]. Compared with CU vaccine, M-9, Minnesota and PM#1 and PM#3 avirulent P. multocida vaccine was not effective in protecting turkeys against fowl cholera [104,122], and has negative effects on body weight gain [123]. A further way to induce attenuation was the use of the streptomycin antibiotics. Streptomycin-dependent P. multocida vaccine provided complete protection for rabbits against homologous infection [78,124], and protected turkeys against fowl cholera [125]. However, live streptomycin-dependent P. multocida A:3 mutant protected rabbits from pasteurellosis induced by homologous and heterologous challenge [126–128], but not A:12 strain [129]. Streptomycin-dependent live P. multocida type A3 and B vaccine protected cattle against hemorrhagic septicemia without any adverse effects [130,131]. The deletion of the gene encoding the P. multocida toxins resulted in the production of an effective live attenuated vaccine against atrophic rhinitis in mice [132]. The live aroA deleted derivative of P. multocida serotype B:2 was used for calves and mice vaccination against hemorrhagic septicemia [44,80]. This safe preparation induced a protection against homologous challenge [133–135]. The marker-free aroA derivative of P. multocida elicited a cross-protective immunity against heterologous challenge [136]. Cross-protection was induced as well by using two live aroA mutants of P. multocida serotype 1 and 3 to protect in chickens against fowl cholera [137]. The aroA attenuated derivatives of two P. multocida serotype B:2 vaccines protected mice against hemorrhagic septicemia [80]. Immunization of pigs with live temperature-sensitive P. multocida mutant induced a humoral response against homologous infection [138]. While, immunization of mice with high doses of P. multocida cexA mutant (PBA875) conferred high protection against P. multocida infection. Moreover, vaccination of mice with acapsular P. multocida strain (AL18) induced high protective immunity against the wild-type infection. However vaccination with killed wild-type or killed AL18 failed to induce immunity [139]. Modifiedlive P. multocida vaccine of calves proved a good potency to increase antibody titer but did not improve the animal’s health or performance [140]. Another example is the live attenuated P. multocida mutant which expresses the N-terminal truncated fragment of P. multocida toxin (N-PMT). It had the potential to be used as powerful vaccine against wild-type challenge in pigs [141]. In 2012 an attenuated P. multocida derivative that only expresses N-PMT was used as a vaccine to prevent atrophic rhinitis due to its potency in inducing high antibodies level in mice [142]. The live attenuated vaccines main advantage is that they induce cross-serotype protection [23] and cellular immunity better than inactivated vaccines [143]. However, they may cause systemic infection, and disease outbreaks [144]. Digested bacterial lysates. In 1968, scientists discovered that the orally administrated P. multocida prepared from the lysate of killed organisms induced high resistance against the homologous challenge in chickens and turkeys [53]. The potassium thiocyanate extract (PTE) of P. multocida conferred high protection and reduction in disease severity in chickens against fowl cholera [145], in mice [146,147], and rabbits [35,148]. This protection is mainly due to the LPS and protein content of the extract [149]. In 1996, Suckow group [150] found that PTE of P. multocida coupled with cholera toxin (CT) enhanced the immune response against homologous


T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

challenge [151], especially when administrated subcutaneously [152] or incorporated with alginate microsphere [153]. Although, cell-free culture filtrate of P. multocida had high ability to immunize turkeys against pasteurellosis [154], it failed to induce cross-protection in turkeys against fowl cholera unless unfiltered [155]. This protection was mainly due to the endotoxin content [156,157]. The complete lysate of P. multocida heated at 56 ◦ C for 1 h provided full cross-protection to turkeys, while 50% cross-protection achieved by trypsin-treated lysate and no cross protection induced with pepsin-treated lysate [158]. The sonication-treated lysate provided higher protection than that of heat-treated one [69]. The controlled expression of cloned PhiX174 gene E of Gramnegative bacteria like P. multocida led to cells lysis and the formation of bacterial ghosts that were used as non-living candidate vaccines called “the recombinant ghost system” [159,160]. Rabbits and mice vaccinated with P. multocida ghosts had high immune response against homologous challenge [161]. This vaccination method has many advantages such as easy production method, safe, and effectiveness [160]. The addition of adjuvant to the supernatant fraction of P. multocida lysate enhanced its protective ability against heterologous and homologous challenge in turkeys. However using this adjuvant with complete lysate did not confer the same role in protection [162]. After two years, membrane vesicles solubilized with the whole supernatant of turkey-grown P. multocida gave variable degree of protection to turkey when challenged with P. multocida infection [163]. The most recent vaccine against P. multocida was based on the outer membrane protein vesicle (OMV). Those are tiny spherical bodies, that protrude from the outer membrane of Gram-negative bacteria. They consist of different membrane proteins, LPS and phospholipids. The intranasal immunization of mice by OMV induced a considerable heterologous humoral and mucosal immunity [164]. 2.2.2. Subunit vaccines Frequently called “second generation vaccines”, subunit vaccines are composed of individual immunogenic components of the pathogen such as the pathogen’s proteins and polysaccharides to elicit immunity. In 1972, Bapat and Sawhney [165] studied the capsular antigen of Pasteurella as vaccine candidate for rabbits. It was later proven that high doses of capsular antigens of P. multocida provided protection to cattle against HS which lasted for 14 months [166–168]. The lipopolysaccharide (LPS) of P. multocida was an effective tool to protect turkey from fowl cholera [169], mice from pasteurellosis [44,170,171]. It was proven that core LPS mutant of Escherichia coli (J5) can be used as useful cross-reacting prophylactic agent against pasteurellosis in rabbits [172]. The protective capacity of the protein fraction of Pasteurella was proven [173]. The immunization with a vaccine containing P. multocida toxin (PMT) protected pigs from rhinitis [174,175], and its formaldehyde toxoid derivative had a maternal potency [176–182]. The heat inactivated PMT protected rabbits from pasteurellosis [183]. However, the immunization of pigs with the dermonecrotic toxin (DNT) of P. multocida type D resulted in high humoral response [184], and protected rats from homologous challenge [185]. Moreover, P. multocida bacterin-toxoid (BT) induced a synergic protective immunity in rabbits higher than that induced with (PMT) alone [151]. The bacterin-toxoid formulation supplied rats with protection against the toxin of P. multocida serotype D [186]. The application of Pasteurella outer membrane protein (OMP) in vaccination started in 1991. The vaccination of rabbits with the OMP of P. multocida against the homologous challenge had the ability to minimize the severity of pneumonia and enhance phagocytosis in rabbits [38,96], cattle [187,188], but not in mice

[189,190] unless coupled with an adjuvant [191,192]. The vaccine based on iron-regulated OMP (IROMP) conferred protection to rabbits [193–195] and calves [196–198]. The native OmpH protein of P. multocida was used as well as a successful vaccine to immunize mice against homologous challenge since it induced high antibody titer and elevated proliferation ability of T-cells [199]. More recently, it was proven that the heat-modifiable OmpA family played a crucial role in enhancing the cellular response against P. multocida [200]. In addition to OMP, bacterial adhesins having a molecular weight of 39 kDa (Cp39) provided cross-protection for mice against homologous challenge [201,202]. In 2002, poultry and other animals were vaccinated against Gram-negative bacteria by a vaccine containing purified siderophore receptor proteins produced by strains of Pasteurella spp. [203]. In 2008, the use of subunit vaccine that contain Pasteurella lipoprotein E (PlpE), but not lipoprotein B was a revolutionary discovery in that time against P. multocida without any adverse effects [204–206]. In 1970, the combined vaccine which consists of culture filtrate, cell wall, and cytoplasm was a promising vaccine to protect turkeys against pasteurellosis [207], this developed later [140,208]. The adjuvancity effect of the PMT on other vaccines preparation was proved [209], especially with alginate encapsulated vaccines [210]. However, polyvalent Pasteurella vaccines induced high immunity and increased the resistance against P. multocida in mice, rabbits [211], calves [83], but not with sheep [212] even when coupled with oil adjuvant [213]. 2.2.3. Recombinant vaccines The use of recombinant vaccines or the so called third generation vaccines played a distinct role in producing vaccines against P. multocida. The first trial was in 1994, when a non-toxic recombinant derivative of the P. multocida toxin (rPMT) induced high response in pigs against rhinitis [214]. This developed by a vaccine consisting of three fragments of recombinant N-fraction of P. multocida toxin (rPMT-N), which provided high antibody titer, and high levels of maternal antibodies in the colostrums [215–218]. The use of novel combined vaccine that consists of rPMT and bacterin was successful to protect swine [219]. However in 1997, immunization of turkeys with recombinant P6-like protein lacked the ability to protect against avian fowl cholera [220]. Ten years later in Korea, Kim et al. [221] showed that the truncated recombinant OmpH protect pigs and mice against pasteurellosis [222–224]. Moreover, recombinant OmpA induced strong but non-protective immunity in mice [225]. In 2008, a study proved that the recombinant tobacco plant harboring OmpH protein of P. multocida A:3 can be used as a carrier system to develop plant-based vaccine against fowl cholera [226]. Chickens and mice were protected against pasteurellosis by using the recombinant adhesive protein (rCp39) [202,227]. Immunization with recombinant filamentous hemagglutinin peptides (rFHAB2) conferred high immune response and cross-protection against fowl cholera in turkeys [228,229] and HS in goats [230]. Recombinant P. multocida lipoprotein E (PlpE) induced cross immunity in mice and chickens against heterologous challenge [231]. The recombinant PlpE or OmpH and lipoprotein E (PlpE) genes fusion (PlpEC-OmpH) showed high ability to be used as vaccine for cattle against shipping fever due to P. multocida [232]. In 2011, Hussaini et al. [233] proved that recombinant clone ABA392 derived from P. multocida serotype B has the potential to provide 83% immunity to mice against hemorrhagic septicemia. Later on the same group proved that the expressed sub-clone CSI57 J of P. multocida serotype B could be a successful tool to vaccinate mice against HS [234]. 2.2.4. DNA vaccines These vaccines are known as the fourth generation vaccines. DNA vaccine derived from P. multocida toxin (PMT) gene showed a protective potency against homologous infection in mice and

T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

swine [235]. In India in 2011, outer membrane protein DNA vaccines were investigated to determine their potency to be used as successful vaccines against hemorrhagic septicemia of cattle and buffaloes [236]. In China in 2011, it was proven that OMP-DNA vaccines such as those of pOmpH, pOmpA of P. multocida could induce partial protection for chickens against avian pasteurellosis, while pOmpHA fusion vaccine conferred higher protection than that of attenuated vaccines [237]. In 2012, scientists tested the potency of three DNA vaccines that consisted of OmpH, PlpEN and PlpEC. Their study showed that these preparations were immunogenic but not protective against P. multocida in mice [232]. One year later, a group of scientists showed that divalent combination of pcDNA-OmpH + pcDNA-OmpA, pOmpH + pOmpA and fusion DNA vaccines had a promising ability to confer immune response in chickens against fowl cholera caused by avian P. multocida, however the monovalent DNA vaccines such as pcDNA-OmpH, pOmpH and pcDNA-OmpA, pOmpA had limited potency [238].

3. Conclusion Several microbial pathogens cause severe losses in the animal husbandry industry. The respiratory infections spread rapidly between the members of the troupes and disseminate to other ones resulting in large scale outbreaks. Pasteurella is a major respiratory infection in farm and wild animals, causing different symptoms of pasteurellosis that range from minor local infection to fatal septicemia. It is one of the most widespread ones, even in countries with low humidity and low temperature weathers that usually limit the spread of several pathogens. It is a highly contagious disease affecting domesticated animals, especially buffalos, poultry, and rabbits. Chemotherapeutic treatment of Pasteurella is expensive, lengthy, and ineffective, as well as being toxic to human consumers. Biosecurity measures may help to diminish the spread of the pathogen, but immunization methods are the most potent tools to prevent it. Although antisera against the microbial extract and OMP showed a considerable potency to control infections, vaccination protocols were the most effective to confer protection against the pathogen. The earliest vaccines against Pasteurella appeared in the mid1950s. Those were the formalin-killed in vitro grown bacteria that are still used till now as major commercial vaccines. They proved to confer a considerable protection against homologous infection for 6–8 weeks in different animals. It was confirmed that heat killed pathogens provide half-protection when compared to the formalin’s; an observation that suggests the major epitope of Pasteurella is a heat labile substance, such as proteins. Although attempts to produce host-passaged isolates induced high cross-immunity against the microbial challenges, it did not last for a longtime since the product was host specific and induced half protection when compared to the previous in vitro-propagated ones. Moreover, trials to produce bacterin from iron-deficient in vitro cultures failed since the vaccine never ensured full cross-protection. Oiladjuvanted formulation showed a variable efficiency in prolonging the bacterin action in cattle for 250 days, ducks, chickens, turkeys, rabbits but not sheep. The addition of saponin synergized that action. The level of protection was not affected by oil formulation but it was correlated to the number of administrations of the vaccine. Alum, Freund’s incomplete adjuvant, PMT toxoid, DNA, and propolis were used simultaneously to enhance the effect of bacterin. In general, the inactivated bacterin lacked the ability to confer cross-protection, long-term immunization and induced local inflammation at the site of injection. P. multocida were attenuated by their incubation with mutagenic substances, streptomycin, or subjected to gene deletion to produce avirulent live strains. Although the produced vaccine was


unsafe when compared to bacterin, it induced cross-protection and cellular response better than the bacterin. However unlike bacterin, it had a therapeutic potency for infected animals. The attenuated vaccine offered a protection of thirty weeks in turkeys, thirteen months in buffaloes, and had a considerable potency when orally administered to poultry. Therefore trials to use attenuated vaccine as a booster for a primary bacterin dose were followed in some research. Starting in 1977, the bacterial lysates by potassium thiocyanate were shown to elicit a protective humoral response against the homologous challenge, especially when adjuvanted with cholera toxin and administered subcutaneously. Unlike pepsin-treated lysate, both the heated bacteria and the bacterial ghosts conferred a reasonable protection. This fact confirms that the main virulent factors of the bacterium are proteins in the cells wall. Subunit vaccines paved the way for use as safe candidates where CPS, LPS, siderophores, PMT, DNT, and lipoprotein E showed to confer reasonable antibody titer against the homologous challenge. Simultaneously, PMT was frequently used as adjuvant for bacterin and PTE. The PMT toxoid, OMP-A/H and the IROMP of strains B2 and B6 were able to induce high humoral and cellular responses. However, the protection obtained from those subunits was homologous, and their extraction was complicated. Therefore, recombinant trials to produce OmpA, OmpH, adhesive protein (Cp39), filamentous hemaglutinin peptides (FHAB2), fimbreal protein, N-fraction PMT, and lipoprotein E were followed since 1997. They conferred maternal potency, and high antibody titer against homologous challenge of the pathogen. As for being relatively cheaper for large scale veterinary use, the DNA vaccines were introduced to combat Pasteurella. DNA encoding for PMT, OmpA, OmpH, and lipoprotein E were tested for that purpose. Although the preparations induced both humoral and cellular responses, they were not protective unless introduced as divalent preparations for OMPs. Though, DNA vaccines appear promising; their use is limited by cost and lack of technological limitations. Although each trend of vaccine groups has its advantages and limitations, the ideal vaccine candidate would be one that confers long-term cross-protection for homologous and heterologous challenges, potent cellular and humoral response, therapeutic activity, prevent the septic shock due to the bacterium, as well as being nonreactogenic, easy to administer to the animals, easy to prepare and conserve, fully safe, and cheap. Although attenuated vaccine against P. multocida were unsafe, they were unique in offering heterologous protection and therapeutic activity. They shared the advantage of offering cellular response together with humoral one with DNA vaccines. Moreover, they may be orally administered, offer prolonged protection for almost a year, and are cheap and easy to produce. While all other type of vaccines lacked those unique criteria. Therefore, the trials to develop their use by reducing their harm are considerable aims. The proposed formulation that offers the majority of the ideal criteria of a vaccine against P. multocida is a dose of well adjuvanted killed vaccine to act itself as a vaccine against possible harm of the attenuated vaccine, followed by orally administered lifetime doses of the attenuated vaccine to attain the desired protection. As described previously, several formulations showed to enhance the activity of killed vaccines especially when supplemented with saponin, or when administered for specific time-intervals. Those regimens are trials of merit for further evaluation.

Acknowledgements The authors would like to thank Miss. Sherine Ahmed and Miss. Dalia Yakout volunteers at the Bibliotheca Alexandrina for the support they offered to retrieve all necessary articles. In parallel to,


T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

Mr. Chris Marrs and Ms. Zoya Waliany volunteers at the Scientific Support and Project Section of the Bibliotheca Alexandrina for their efforts to edit this review. References [1] Pastoret PP. Veterinary vaccinology. C R Acad Sci III 1999;322:967–72. [2] Meeusen ENT, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin Microbiol Rev 2007;20:489–510. [3] Alexander MM, Sawin PB, Roehm DA. Respiratory infection in the rabbit: an enzootic caused by Pasteurella lepiseptica and attempts to control it by vaccination. J Infect Dis 1952;90:30–3. [4] Webster LT. The epidemiology of a rabbit respiratory infection: introduction. J Exp Med 1924;39:837–41. [5] Coudert P, Rideaud P, Virag G, Cerrone A. Pasteurellosis in rabbits. Rec Adv Rabbit Sci 2006;3:147–62. [6] Rad M, Movassaghi AR, Sharifi K, Naseri Z, Seifi HA. Two outbreaks of Pasteurella multocida septicemia in neonatal lambs. Comp Clin Pathol 2011;20:57–9. [7] Chandrasekaran S, Kennett L, Yeap PC, Muniandy N, Rani B, Mukkur TKS. Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines. Vet Microbiol 1994;41:213–9. [8] Mohamed RA, Abdelsalam EB. A review on pneumonic pasteurellosis (respiratory mannheimiosis) with emphasis on pathogenesis, virulence mechanisms and predisposing factors. Bulg J Vet Med 2008;11:139–60. [9] Boudreaux CM. A novel strategy of controlling bovine pneumonic pasteurellosis: transfecting the upper respiratory tract of cattle with a gene coding for the antimicrobial peptide Cecropin B [MSc]. New Orleans: Louisiana State University; 2004. [10] McVey DS. BRD research needs in the next 10–20 years. Anim Health Res Rev 2009;10:165–7. [11] Cameron RDA, O’Boyle D, Frost AJ, Gordon AN, Fegan N. An outbreak of haemorrhagic septicaemia associated with Pasteurella multocida subsp gallicida in a large pig herd. Aust Vet J 1996;73:27–9. [12] Blackall PJ, Fegan N, Pahoff JL, Storie GJ, McIntosh GB, Cameron RDA, et al. The molecular epidemiology of four outbreaks of porcine pasteurellosis. Vet Microbiol 2000;72:111–20. [13] Ibrahim RS, Sawada T, Shahata M, Ibrahim A. Cross-protection and antigen expression by chicken embryo-grown Pasteurella multocida in chickens. J Comp Pathol 2000;123:278–84. [14] Heddleston KL, Hall WJ. Studies on pasteurellosis. II. Comparative efficiency of killed vaccines against fowl cholera in chickens. Avian Dis 1958;2: 322–35. [15] Pedersen K, Dietz HH, Jørgensen JC, Christensen TK, Bregnballe T, Andersen TH. Pasteurella multocida from outbreaks of avian cholera in wild and captive birds in Denmark. J Wildl Dis 2003;39:808–16. [16] Kondgen S, Leider M, Lankester F, Bethe A, Lubke-Becker A, Leendertz FH, et al. Pasteurella multocida involved in respiratory disease of wild chimpanzees. PLoS ONE 2011;6:e24236. [17] Weber DJ, Wolfson JS, Swartz MN, Hooper DC. Pasteurella multocida infections: report of 34 cases and review of literature. Medicine (Baltimore) 1984;63:133–54. [18] Davies RL, MacCorquodale R, Reilly S. Characterisation of bovine strains of Pasteurella multocida and comparison with isolates of avian, ovine and porcine origin. Vet Microbiol 2004;99:145–58. [19] Ewers C, Lubke-Becker A, Bethe A, Kiebling S, Filter M, Wieler LH. Virulence genotype of Pasteurella multocida strains isolated from different hosts with various disease status. Vet Microbiol 2006;114:304–17. [20] Kumar AA, Shivachandra SB, Biswas A, Singh VP, Srivastava SK. Prevalent serotypes of Pasteurella multocida isolated from different animal and avian species in India. Vet Res Commun 2004;28:657–67. [21] Arumugam ND, Ajam N, Blackall PJ, Asiah NM, Ramlan M, Maria J, et al. Capsular serotyping of Pasteurella multocida from various animal hosts – a comparison of phenotypic and genotypic methods. Trop Biomed 2011;28:55–63. [22] Taylor JD, Fulton RW, Lehenbauer TW, Step DL, Confer AW. The epidemiology of bovine respiratory disease: what is the evidence for predisposing factors. Can Vet J 2010;51:1095–102. [23] Gyles CL, Prescott JF, Songer JG, Thoen CO. Pathogenesis of bacterial infections in animals. 3rd ed. Iowa: Wiley-Blackwell; 2004. [24] Klein NC, Cunha BA. Pasteurella multocida pneumonia. Semin Respir Infect 1997;12:54–6. [25] Chang WH, Carter GR. Multiple drug resistance in Pasteurella multocida and Pasteurella haemolytica from cattle and swine. J Am Vet Med Assoc 1976;169:710–2. [26] Kehrenberg C, Tanzil GS, Martel JL, Dancla EC, Schwarz S. Antimicrobial resistance in Pasteurella and Mannheimia: epidemiology and genetic basis. Vet Res 2001;32:323–39. [27] Kehrenberg C, Salmon SA, Watts JL, Schwarz S. Tetracycline resistance genes in isolates of Pasteurella multocida, Mannheimia haemolytica, Mannheimia glucosida and Mannheimia varigena from bovine and swine respiratory disease: intergeneric spread of the tet(H) plasmid pMHT1. J Antimicrob Chemother 2001;48:631–40.

[28] Coates ARM, Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 2007;152:1147–54. [29] Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064–73. [30] Carter PB. The current state of veterinary vaccines: is there hope for the future. J Vet Med Ed 2003;30:152–4. [31] Baba T. Cell-mediated immune protection in chickens against Pasteurella multocida. Res Vet Sci 1984;36:225–30. [32] Toth TE, Pyle RH, Caceci T, Siegel PB, Ochs D. Cellular defense of the avian respiratory system: influx and nonopsonic phagocytosis by respiratory phagocytes activated by Pasteurella multocida. Infect Immun 1988;56:1171–9. [33] Toth TE, Siegel PB. Cellular defense of the avian respiratory system: dose–response relationship and duration of response in intratracheal stimulation of avian respiratory phagocytes by a Pasteurella multocida bacterin. Avian Dis 1993;37:756–62. [34] Bierer BW, Derieux WT. The ability of blood plasma from drinking water vaccinated turkeys to protect against a lethal challenge of Pasteurella multocida. Poult Sci 1975;54:2091–3. [35] Lu YS, Pakes SP, Massey L, Stefanu C. A potassium thiocyanate extract vaccine prepared from Pasteurella multocida 3:A protects rabbits against homologous challenge. Infect Immun 1987;55:2967–76. [36] Wijewardana TG, Wilson CF, Gilmour NJ, Poxton IR. Production of mouse monoclonal antibodies to Pasteurella multocida type A and the immunological properties of a protective anti-lipopolysaccharide antibody. J Med Microbiol 1990;33:217–22. [37] Lu YS, Lai WC, Pakes SP, Nie LC. A monoclonal antibody against a Pasteurella multocida outer membrane protein protects rabbits and mice against pasteurellosis. Infect Immun 1991;59:172–80. [38] Lu YS, Lai WC, Pakes SP, Stefanu C. The outer membrane of Pasteurella multocida 3:A protects rabbits against homologous challenge. Infect Immun 1991;59:4517–23. [39] Lu YS, Aguila HN, Lai WC, Pakes SP. Antibodies to outer membrane proteins but not to lipopolysaccharide inhibit pulmonary proliferation of Pasteurella multocida in mice. Infect Immun 1991;59:1470–5. [40] Srivastava SK. Immunogenicity of protein fractions of Pasteurella multocida in animals. Indian J Anim Sci 1999;69:653–6. [41] Vasfi Marandi M, Mittal KR. Role of outer membrane protein H (OmpH)- and OmpA-specific monoclonal antibodies from hybridoma tumors in protection of mice against Pasteurella multocida. Infect Immun 1997;65:4502–8. [42] Adler B, Bulach D, Chung J, Doughty S, Hunt M, Rajakumar K, et al. Candidate vaccine antigens and genes in Pasteurella multocida. J Biotechnol 1999;73:83–90. [43] Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine respiratory disease. Anim Health Res Rev 2007;8:129–50. [44] Adler B, Chancellor R, Homchampa P, Hunt M, Ruffolo C, Strugnell R, et al. Immunity and vaccine development in Pasteurella multocida infections. J Biotechnol 1996;44:139–44. [45] Sutherland AD, Davies RC, Murray J. An experimental anti-idiotype vaccine mimicking lipopolysaccharide gives protection against Pasteurella multocida type A infection in mice. FEMS Immunol Med Microbiol 1993;7:105–10. [46] Fischer G, Conceicao FR, Leite FP, Dummer LA, Vargas GD, Hubner Sde O, et al. Immunomodulation produced by a green propolis extract on humoral and cellular responses of mice immunized with SuHV-1. Vaccine 2007;25:1250–6. [47] Carter GR. Studies on a Pasteurella multocida chicken embryo vaccine. II. Typespecific nature of immunity elicited by a monovalent Pasteurella multocida vaccine. Am J Vet Res 1951;12:326–8. [48] Luk’ianchenko AV. An emulsified vaccine against Pasteurella infections in swine. Veterinariia 1967;44:48–50. [49] Farid AH, Torky HA, el-Nimr MM, Akeula M, Ezzat M. Studies on Pasteurella multocida of birds. Fourth communication: a new polyvalent oil-adjuvant vaccine. Arch Exp Veterinarmed 1987;41:208–11. [50] Bechtol DT, Jones GF. Can a Pasteurella vaccine prevent respiratory disease in calves in a backgrounding lot. Vet Med 1996;91:1042–5. [51] Joshi VB. Immune response to some fractions of Pasteurella multocida (carter’s type B). Indian Vet J 1997;74:641–4. [52] Cismileanu A. A subunit Pasteurella multocida vaccine. Bacteriol Virusol Parazitol Epidemiol (Bucharest, Romania: 1990) 1998;43:98. [53] Heddleston KL, Rebers PA. Fowl cholera: active immunity induced in chickens and turkeys by oral administration of killed Pasteurella multocida. Avian Dis 1968;12:129–34. [54] Heddleston KL, Rebers PA. Fowl cholera: cross-immunity induced in turkeys with formalin-killed in-vivo-propagated Pasteurella. Avian Dis 1972;16:578–86. [55] Heddleston KL, Rebers PA. Fowl cholera bacterins: host-specific crossimmunity induced in turkeys with Pasteurella multocida propagated in embryonating turkey eggs. Avian Dis 1974;18:231–9. [56] Rebers PA, Heddleston KL. Fowl cholera: induction of cross-protection in turkeys with bacterins prepared from host-passaged Pasteurella multocida. Avian Dis 1977;21:50–6. [57] Baljer G, Chorherr S, Mayr A. Wirksamkeit und Unschädlichkeit von Pasteurella multocida-Vaccinen aus inaktivierten Keimen nach subkutaner, oraler und intranasaler Applikation bei der Maus. Zentralbl Veterinarmed B 1982;29:275–83 [in German]. [58] Hamdy AH, Pounden WD, Bell DS. Effect of Pasteurella bacterin on mortality and pneumonia in lambs. J Am Vet Med Assoc 1963;142:379–81. [59] Dowling A, Hodgson JC, Dagleish MP, Eckersall PD, Sales J. Pathophysiological and immune cell responses in calves prior to and following lung

T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

[60] [61]


[63] [64]

[65] [66] [67]







[74] [75]

[76] [77]









[86] [87]


challenge with formalin-killed Pasteurella multocida biotype A:3 and protection studies involving subsequent homologous live challenge. Vet Immunol Immunopathol 2004;100:197–207. Heddleston KL, Gallagher JE, Rebers PA. Fowl cholera: immune response in turkeys. Avian Dis 1970;14:626–35. Bierer BW, Derieux WT. Immunologic response of turkeys to an avirulent Pasteurella multocida vaccine in the drinking water. 2. Duration of immunity. Poult Sci 1972;51:1402–8. Dua SK, Maheswaran SK. Studies on Pasteurella multocida. VI. Nature of systemic immunity and analysis of the correlation between levels of immunity induced by various fowl cholera vaccines and protection against challenge. Avian Dis 1978;22:748–64. Okerman L, Spanoghe L. Immunity induced in mice by Pasteurella multocida strains isolated from rabbits. Zentralbl Veterinarmed B 1980;27:759–63. Okerman L, Spanoghe L. Protective effects of inactivated Pasteurella vaccines in specific pathogen free rabbits. Comp Immunol Microbiol Infect Dis 1981;4:223–8. Layton HW. Efficacy of broth-grown Pasteurella multocida bacterins in ducklings. Avian Dis 1984;28:1086–95. Cardella MA, Adviento MA, Nervig RM. Vaccination studies against experimental bovine Pasteurella pneumonia. Can J Vet Res 1987;51:204–11. ´ Borkowska-Opacka B, Kedrak A, Truszczynski M. Evaluation of the immunogenicity of the vaccine against Pasteurella multocida infections in calves. Bull Vet Inst Pulawy 1999;43:155–66. Burns KE, Ruiz J, Glisson JR. Evaluation of the effect of heating an oil-emulsion Pasteurella multocida bacterin on tissue reaction and immunity. Avian Dis 2003;47:54–8. Garrido ME, Bosch M, Bigas A, Badiola I, Barbe J, Llagostera M. Heterologous protective immunization elicited in mice by Pasteurella multocida fur ompH. Int Microbiol 2008;11:17–24. Okerman L, Devriese LA. Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit Pasteurella multocida vaccine. Vaccine 1987;5:315–8. Avakian AP, Dick JW, Derieux WT. Fowl cholera immunity induced by various vaccines in broiler minibreeder chickens determined by enzyme-linked immunosorbent assay. Avian Dis 1989;33:97–102. Gunawardana GA, Frost AJ, Wilkie I. Study of the immunological response of chickens to P. multocida bacterins with and without adjuvant by immunoblotting. Br Poult Sci 2004;45(Suppl. 1):S40–1. Belloc C, Dupuis L, Deville S, Aucouturier J, Laval A. Evaluation of safety and immune response induced by several adjuvants included in Pasteurella multocida vaccines in chickens. Rev Med Vet – Toulouse 2008;159:371–5. Nassar SA, Mohamed AH, Soufy H, Nasr SM, Mahran KM. Immunostimulant effect of Egyptian propolis in rabbits. Sci World J 2012;2012:901516. Kumar S, Chaturvedi VK, Kumar B, Kumar P, Somarajan SR, Kumar A, et al. Improved humoral immune response of oil adjuvant vaccine by saponin coadjuvantation against haemorrhagic septicaemia in mice and buffalo calves. Indian J Anim Sci 2012;82:953–7. Verma R, Jaiswal TN. Haemorrhagic septicaemia vaccines. Vaccine 1998;16:1184–92. Verma R, Jaiswal TN. Protection, humoral and cell-mediated immune responses in calves immunized with multiple emulsion haemorrhagic septicaemia vaccine. Vaccine 1997;15:1254–60. Mosier DA, Panciera RJ, Rogers DP, Uhlich GA, Butine MD, Confer AW, et al. Comparison of serologic and protective responses induced by two Pasteurella vaccines. Can J Vet Res 1998;62:178–82. Shah NH, de Graaf FK. Protection against haemorrhagic septicaemia induced by vaccination of buffalo calves with an improved oil adjuvant vaccine. FEMS Microbiol Lett 1997;155:203–7. Tabatabaei M, Liu Z, Finucane A, Parton R, Coote J. Protective immunity conferred by attenuated aroA derivatives of Pasteurella multocida B:2 strains in a mouse model of hemorrhagic septicemia. Infect Immun 2002;70: 3355–62. Shah NH, Jacobs AA, de Graaf FK. Safety and efficacy of an oil-adjuvant vaccine against haemorrhagic septicaemia in buffalo calves: cross-protection between the serotypes B:2,5 and E:2,5. Vet Rec 2001;149:583–7. ´ ´ Borkowska-Opacka B, Rutkowska-Jurga I, Truszczynski M, Kozaczynski W. An attempt to evaluate the efficacy of vaccines against pasteurellosis in rabbits. Bull Vet Inst Pulawy 1996;40:3–9. Cho YS, Lee HS, Lim SK, Joo YS, Kim JM, Kim JH. Safety and efficacy testing of a novel multivalent bovine bacterial respiratory vaccine composed of five bacterins and two immunogens. J Vet Med Sci 2008;70:959–64. Rawat M, Jaiswal TN. Immunomodulation of water-in-oil-in-water (w/o/w) emulsion vaccines of killed Pasteurella multocida (P52 ) whole cells grown under iron-regulated conditions. Indian J Anim Sci 2004;74: 701–5. Glisson JR, Contreras MD, Cheng IHN, Wang C. Cross-protection studies with Pasteurella multocida bacterins prepared from bacteria propagated in irondepleted medium. Avian Dis 1993;37:1074–9. Mariana S, Hirst R. The immunogenicity and pathogenicity of Pasteurella multocida isolated from poultry in Indonesia. Vet Microbiol 2000;72:27–36. Filia G, Jand SK, Arora AK, Oberoi MS. Comparative efficacy of whole cell vaccines prepared from Pasteurella multocida grown under different growth conditions. Indian J Anim Sci 2007;77:119–22. Herath C, Kumar P, Singh M, Kumar D, Ramakrishnan S, Goswami TK, et al. Experimental iron-inactivated Pasteurella multocida A:1 vaccine adjuvanted

[89] [90]

[91] [92]


[94] [95] [96] [97] [98] [99]




[103] [104] [105]


[107] [108] [109] [110]


[112] [113] [114]

[115] [116]

[117] [118]


[120] [121] [122]


with bacterial DNA is safe and protects chickens from fowl cholera. Vaccine 2010;28:2284–9. Ahmed OA, Olson LD, McCune EL. Tissue irritation induced in turkeys by fowl cholera bacterins. Avian Dis 1974;18:590–601. Chengappa MM, McLaughlin BG, Kadel WL, Maddux RL, Greer SC. Efficacy of a live Pasteurella multocida vaccine for the prevention of experimentally induced bovine pneumonic pasteurellosis. Vet Microbiol 1989;21:147–54. Myint A, Carter GR. Prevention of haemorrhagic septicaemia in buffaloes and cattle with a live vaccine. Vet Rec 1989;124:508–9. Myint A, Jones TO, Nyunt HH. Safety efficacy and cross-protectivity of a live intranasal aerosol haemorrhagic septicaemia vaccine. Vet Rec 2005;156:41–5. Cassirer EF, Rudolph KM, Fowler P, Coggins VL, Hunter DL, Miller MW. Evaluation of ewe vaccination as a tool for increasing bighorn lamb survival following pasteurellosis epizootics. J Wildl Dis 2001;37:49–57. Schimmel D. Further development of P. multocida vaccines for swine. Berl Munch Tierarztl Wochenschr 1990;103:410–1. Hazarika MP, Barman NN, George S. Humoral immune response of mice immunized with P. multocida of pig origin. Indian Vet J 2011;88:9–11. Srivastava SK. Immunogenicity of Pasteurella multocida grown in ironrestricted medium. Indian J Anim Sci 1998;13:137–44. Chung JY, Wilkie I, Boyce JD, Adler B. Vaccination against fowl cholera with acapsular Pasteurella multocida A:1. Vaccine 2005;23:2751–5. Wong JC, Kucera CJ. Cross-protection by a chemically altered vaccinal strain of Pasteurella multocida in mice and hamsters. Am J Vet Res 1982;43:1315–6. Maheswaran SK, McDowell JR, Pomeroy BS. Studies on Pasteurella multocida. I. Efficacy of an avirulent mutant as a live vaccine in turkeys. Avian Dis 1973;17:396–405. Hertman I, Markenson J, Michael A, Geier E. Attenuated live fowl cholera vaccine. I. Development of vaccine strain M3G of Pasteurella multocida. Avian Dis 1979;23:863–9. Michael A, Geier E, Konshtok R, Hertman I, Markenson J. Attenutated live fowl cholera vaccine. III. Laboratory and field vaccination trials in turkeys and chickens. Avian Dis 1979;23:878–85. Olson LD. Evaluation of two avirulent vaccines for preventing experimental fowl cholera in turkeys, and use of one vaccine in the field. Avian Dis 1977;21:178–84. Rice JT, Bierer BW, Dick JW. Vaccination of chickens through the drinking water with a live, Pasteurella multocida, vaccine. Poult Sci 1979;58:18–22. Friedlander RC, Olson LD, McCune EL. Comparison of live avirulent M-9, minnesota, and CU fowl cholera vaccines. Avian Dis 1991;35:251–6. Dabbert CB, Lochmiller RL, Morton RJ, Powell KC. A pathogenic challenge model for adult northern bobwhite (Colinus virginianus) using a vaccine strain of Pasteurella multocida type 3. Avian Dis 1996;40:99–102. Dua SK, Maheswaran SK. Studies on Pasteurella multocida. VII. Dynamics and temporal development of local humoral immunity induced by a live avirulent fowl cholera vaccine. Avian Dis 1978;22:771–7. Jones JE, Derieux WT, Hughes BL, Dick JW. Effect of cholera preventative treatments on reproductive performance of turkey hens. Poult Sci 1978;57:523–6. Rice JT, Dick JW, Bierer BW. Subcutaneous vaccination of chickens with a live, avirulent Pasteurella multocida vaccine. Poult Sci 1978;57:1514–8. Bierer BW, Eleazer TH. Continuous use of a live vaccine in the drinking wate against fowl cholera infection in turkeys. Poult Sci 1968;47:1258–60. Heddleston KL, Rebers PA, Wessman G. Fowl cholera: immunologic and serologic response in turdeys to live Pasteurella multocida vaccine administered in the drinking water. Poult Sci 1975;54:217–21. Bierer BW. An evaluation of the effect of various concentrations of the Clemson University Pasteurella multocida drinking water vaccine on the immune response against fowl cholera disease in turkey. Poult Sci 1977;56:327–30. Coates SR, Jensen MM, Brown ED. The response of turkeys to varying doses of live oral Pasteurella multocida vaccine. Poult Sci 1977;56:273–6. Derieux WT. Immune response of medicated turkeys vaccinated with live Pasteurella multocida. Am J Vet Res 1977;38:487–9. Maheswaran SK, Dua SK, Thies ES. Studies on Pasteurella multocida. IX. Levamisole-induced augmentation of immune responses to a live fowl cholera vaccine. Avian Dis 1980;24:71–81. Derieux WT, Dick JW. The response of broiler breeder chickens to parenteral administration of avirulent Pasteurella multocida. Avian Dis 1980;24:743–50. Ghazikhanian GY, Dungan WM, Kelly BJ. Immunization of turkey breeder hens against fowl cholera by combined oral and wing-web administration of attenuated (CU) Pasteurella multocida. Avian Dis 1983;27:133–40. Derieux WT. Response of broiler-type chickens to live Pasteurella multocidaduration of immunity and minimum dose. Avian Dis 1984;28:281–4. Briggs DJ, Whitfill CE, Skeeles JK. Probability of survival based on ELISA titer following challenge of vaccinated chickens with the X-73 strain of Pasteurella multocida. Avian Dis 1985;29:904–11. Olson LD, Schlink GT. Onset and duration of immunity and minimum dosage with CU cholera vaccine in turkeys via drinking water. Avian Dis 1986;30:87–92. Schlink GT, Olson LD. Fowl cholera vaccination of growing turkeys with CU strain via routes other than oral. Avian Dis 1987;31:22–8. Dick JW, Avakian AP. Response of broiler chickens to fowl cholera vaccination at 1 to 6 weeks of age. Avian Dis 1991;35:761–6. Hofacre CL, Glisson JR, Kleven SH. Evaluation of Pasteurella multocida mutants of low virulence. II. Immunologic response of turkeys. Avian Dis 1989;33:275–8.


T.A. Ahmad et al. / Vaccine 32 (2014) 909–917

[123] Hopkins BA, Olson LD. Comparison of live avirulent PM-1 and CU fowl cholera vaccines in turkeys. Avian Dis 1997;41:317–25. [124] Wei BD, Carter GR. Live streptomycin-dependent Pasteurella multocida vaccine for the prevention of hemorrhagic septicemia. Am J Vet Res 1978;39:1534–7. [125] Chengappa MM, Carter GR, Chang TS. A streptomycin-dependent live Pasteurella multocida type-3 vaccine for the prevention of fowl cholera in turkeys. Avian Dis 1979;23:57–61. [126] Chengappa MM, Myers RC, Carter GR. A streptomycin dependent live Pasteurella multocida vaccine for the prevention of rabbit pasteurellosis. Lab Anim Sci 1980;30:515–8. [127] Lu YS, Pakes SP. Protection of rabbits against experimental pasteurellosis by a streptomycin-dependent Pasteurella multocida serotype 3:A live mutant vaccine. Infect Immun 1981;34:1018–24. [128] Digiacomo RF, Deeb BJ, Bernard BL, Klaassen JM, Chengappa MM. Safety and efficacy of a streptomycin dependent live Pasteurella multocida vaccine in rabbits. Lab Anim Sci 1987;37:187–90. [129] Deeb BJ, DiGiacomo RF, Bernard BL, Silbernagel SM, Chengappa MM. Field trial of a live streptomycin dependent Pasteurella multocida serotype A:12 vaccine in rabbits. Lab Anim Sci 1989;39:229–33. [130] Alwis MCL, Carter GR. Preliminary field trials with a streptomycin-dependent vaccine against haemorrhagic septicaemia. Vet Rec 1980;106:435–7. [131] Catt DM, Chengappa MM, Kadel WL, Herren CE. Preliminary studies with a live streptomycin-dependent Pasteurella multocida and Pasteurella haemolytica vaccine for the prevention of bovine pneumonic pasteurellosis. Can J Comp Med 1985;49:366–71. [132] Petersen SK, Foged NT, Bording A, Nielsen JP, Riemann HK, Frandsen PL. Recombinant derivatives of Pasteurella multocida toxin: candidates for a vaccine against progressive atrophic rhinitis. Infect Immun 1991;59:1387–93. [133] Hodgson JC, Finucane A, Dagleish MP, Ataei S, Parton R, Coote JG. Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration. Infect Immun 2005;73:1475–81. [134] Dagleish MP, Hodgson JC, Ataei S, Finucane A, Finlayson J, Sales J, et al. Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves. Infect Immun 2007;75:5837–44. [135] Ataei S, Burchmore R, Christopher Hodgson J, Finucane A, Parton R, Coote JG. Identification of immunogenic proteins associated with protection against haemorrhagic septicaemia after vaccination of calves with a liveattenuated aroA derivative of Pasteurella multocida B:2. Res Vet Sci 2009;87: 207–10. [136] Homchampa P, Strugnell RA, Adler B. Cross protective immunity conferred by a marker-free aroA mutant of Pasteurella multocida. Vaccine 1997;15:203–8. [137] Scott PC, Markham JF, Whithear KG. Safety and efficacy of two live Pasteurella multocida aro-A mutant vaccines in chickens. Avian Dis 1999;43:83–8. [138] Muller G, Kohler H, Diller R, Erler W. Antibody reactions after aerogenous or subcutaneous immunization of pigs with Pasteurella multocida antigens. Vaccine 2000;19:751–7. [139] Boyce JD, Adler B. Acapsular Pasteurella multocida B:2 can stimulate protective immunity against pasteurellosis. Infect Immun 2001;69:1943–6. [140] Aubry P, Warnick LD, Guard CL, Hill BW, Witt MF. Health and performance of young dairy calves vaccinated with a modified-live Mannheimia haemolytica and Pasteurella multocida vaccine. J Am Vet Med Assoc 2001;219:1739–42. [141] Seo J, Lee S, Pyo H, Lee J, Kim T. Protective potential of an attenuated Pasteurella multocida, which expresses only the N-terminal truncated fragment of P. multocida toxin. Can J Vet Res 2010;74:25–9. [142] Kim T, Son C, Lee J, Kim K. Vaccine potential of an attenuated Pasteurella multocida that expresses only the N-terminal truncated fragment of P. multocida toxin in pigs. Can J Vet Res 2012;76:69–71. [143] Haesebrouck F, Pasmans F, Chiers K, Maes D, Ducatelle R, Decostere A. Efficacy of vaccines against bacterial diseases in swine: what can we expect. Vet Microbiol 2004;100:255–68. [144] Hopkins BA, Huang TH, Olson LD. Differentiating turkey postvaccination isolants of Pasteurella multocida using arbitrarily primed polymerase chain reaction. Avian Dis 1998;42:265–74. [145] Gaunt G, Moffat R, Mukkur TK. Fowl cholera: immunization of chickens with potassium thiocyanate (KSCN) extract of Pasteurella multocida serotype 3. Avian Dis 1977;21:543–8. [146] Mukkur TK. Immunogenicity of a chaotropically extracted protective antigen(s) of Pasteurella multocida type A (bovine origin) against experimental pasteurellosis in mice. J Gen Microbiol 1979;113:37–43. [147] Smith RH, Babiuk LA, Stockdale PH. Intranasal immunization of mice against Pasteurella multocida. Infect Immun 1981;31:129–35. [148] Ringler DH, Peter GK, Chrisp CE, Keren DF. Protection of rabbits against experimental pasteurellosis by vaccination with a potassium thiocyanate extract of Pasteurella multocida. Infect Immun 1985;49:498–504. [149] Ryu H, Kaeberle ML. Immunogenicity of potassium thiocyanate extract of type A Pasteurella multocida. Vet Microbiol 1986;11:373–85. [150] Suckow MA, Bowersock TL, Nielsen K, Grigdesby CF. Enhancement of respiratory immunity to Pasteurella multocida by cholera toxin in rabbits. Lab Anim 1996;30:120–6. [151] Suckow MA. Immunization of rabbits against Pasteurella multocida using a commercial swine vaccine. Lab Anim 2000;34:403–8. [152] Suckow MA, Haab RW, Miloscio LJ, Guilloud NB. Field trial of a Pasteurella multocida extract vaccine in rabbits. J Am Assoc Lab Anim Sci 2008;47:18–21.

[153] Suckow MA, Bowersock TL, Park H, Park K. Oral immunization of rabbits against Pasteurella multocida with an alginate microsphere delivery system. J Biomater Sci 1997;8:131–9. [154] Ficken MD, Barnes HJ, Qureshi MA. Vaccination of turkeys with cell-free culture filtrate of Pasteurella multocida. Avian Dis 1991;35:126–34. [155] Rimler RB, Rebers PA, Rhoades KR. Fowl cholera: cross-protection induced by Pasteurella multocida separated from infected turkey blood. Avian Dis 1979;23:730–41. [156] Ficken MD, Barnes HJ, Avakian AP, Carver DK. Vaccination of turkeys with cellfree culture filtrate of Pasteurella multocida: effects of dilution, iron chelation, and heterologous challenge. Avian Dis 1992;36:975–85. [157] Ficken MD, Barnes HJ, Avakian AP, Carver DK. Vaccination of turkeys with cell-free culture filtrate of Pasteurella multocida: effects of ultrafiltration and endotoxin removal. Avian Dis 1992;36:423–31. [158] Brogden KA, Rimler RB. Lysates of turkey-grown Pasteurella multocida: examination of vaccine preparations by electron microscopy. Am J Vet Res 1982;43:1781–5. [159] Eko FO, Witte A, Huter V, Kuen B, Furst-Ladani S, Haslberger A, et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 1999;17:1643–9. [160] Jalava K, Hensel A, Szostak M, Resch S, Lubitz W. Bacterial ghosts as vaccine candidates for veterinary applications. J Control Release 2002;85:17–25. [161] Marchart J, Dropmann G, Lechleitner S, Schlapp T, Wanner G, Szostak MP, et al. Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 2003;21:3988–97. [162] Rimler RB, Rhoades KR. Lysates of turkey-grown Pasteurella multocida: protection against homologous and heterologous serotype challenge exposures. Am J Vet Res 1981;42:2117–21. [163] Brogden KA, Rimler RB. Lysates of turkey grown Pasteurella multocida: effects of solubilizing agents on the immunologic properties of membrane vesicles. Am J Vet Res 1983;44:428–32. [164] Roier S, Fenninger JC, Leitner DR, Rechberger GN, Reidl J, Schild S. Immunogenicity of Pasteurella multocida and Mannheimia haemolytica outer membrane vesicles. Int J Med Microbiol 2013;303:247–56. [165] Bapat JA, Sawhney AN. Studies on the somatic and capsular antigens of Pasteurella multocida as protection inducing factors in rabbits. Indian J Pathol Bacteriol 1972;15:73–5. [166] Nagy LK, Penn CW. Protection of cattle against experimental haemorrhagic septicaemia by the capsular antigens of Pasteurella multocida, types B and E. Res Vet Sci 1976;20:249–53. [167] Brown SL, McKinney FT, Klein GC, Jones WL. Evaluation of a safranin-O-stained antigen microagglutination test for Francisella tularensis antibodies. J Clin Microbiol 1980;11:146–8. [168] Maslog FS. Immunity provided by haemorrhagic septicaemia-subunit vaccine in ruminants. Dev Biol Stand 1998;92:301–7. [169] Kodama H, Matsumoto M, Fuquay JI, Syuto B. Soluble fractions of Pasteurella multocida: their protective qualities against fowl cholera in turkeys. Avian Dis 1983;27:283–91. [170] Muniandyl N, Mukkur TKS. Protective potential of purified lipopolysaccharide versus conjugated oligosaccharide of Pasteurella multocida type B in mice. ACIAR Proc 1993;149:149. [171] Muniandy N, Love DN, Mukkur TK. Immunogenicity of purified lipopolysaccharide or protein–oligosaccharide conjugates of Pasteurella multocida type 6:B in mice. Comp Immunol Microbiol Infect Dis 1998;21:257–79. [172] Corbeil LB, Strayer DS, Skaletsky E, Wunderlich A, Sell S. Immunity to pasteurellosis in compromised rabbits. Am J Vet Res 1983;44:845–50. [173] Brar RS, Kaur P, Arora AK, Jand SK. Protective efficacy of purified protein fractions of Pasteurella multocida in mice. Indian Vet J 2010;87:537–40. [174] Pedersen KB, Barfod K. Effect on the incidence of atrophic rhinitis of vaccination of sows with a vaccine containing Pasteurella multocida toxin. Nord Vet Med 1982;34:293–302. [175] Van Diemen PM, De Vries Reilingh G, Parmentier HK. Immune responses of piglets to Pasteurella multocida toxin and toxoid. Vet Immunol Immunopathol 1994;41:307–21. [176] Foged NT, Nielsen JP, Jorsal SE. Protection against progressive atrophic rhinitis by vaccination with Pasteurella multocida toxin purified by monoclonal antibodies. Vet Rec 1989;125:7–11. [177] Nielsen JP, Foged NT, Sorensen V, Barfod K, Bording A, Petersen SK. Vaccination against progressive atrophic rhinitis with a recombinant Pasteurella multocida toxin derivative. Can J Vet Res 1991;55:128–38. [178] Bording A, Foged NT. Characterization of the immunogenicity of formaldehyde detoxified Pasteurella multocida toxin. Vet Microbiol 1991;29: 267–80. [179] Foged NT. Pasteurella multocida toxin. The characterisation of the toxin and its significance in the diagnosis and prevention of progressive atrophic rhinitis in pigs. APMIS Suppl 1992;25:1–56. [180] Confer AW. Immunogens of Pasteurella. Vet Microbiol 1993;37:353–68. [181] To H, Someno S, Nagai S. Development of a genetically modified nontoxigenic Pasteurella multocida toxin as a candidate for use in vaccines against progressive atrophic rhinitis in pigs. Am J Vet Res 2005;66:113–8. [182] Lee J, Kang HE, Woo HJ. Protective immunity conferred by the C-terminal fragment of recombinant Pasteurella multocida toxin. Clin Vaccine Immunol 2012;19:1526–31. [183] Suckow MA, Bowersock TL, Nielsen K, Chrisp CE, Frandsen PL, Janovitz EB. Protective immunity to Pasteurella multocida heat-labile toxin by intranasal immunization in rabbits. Lab Anim Sci 1995;45:526–32.

T.A. Ahmad et al. / Vaccine 32 (2014) 909–917 [184] Frymus T, Muller E, Franz B, Petzoldt K. Protection by toxoid-induced antibody of gnotobiotic piglets challenged with the dermonecrotic toxin of Pasteurella multocida. Zentralbl Veterinarmed B 1989;36:674–80. [185] Thurston JR, Rimler RB, Ackerman MR, Cheville NF, Sacks JM. Immunity induced in rats vaccinated with toxoid prepared from heat-labile toxin produced by Pasteurella multocida serogroup D. Vet Microbiol 1991;27:169–74. [186] Thurston JR, Rimler RB, Ackerman MR, Cheville NF. Use of rats to compare atrophic rhinitis vaccines for protection against effects of heat-labile protein toxin produced by Pasteurella multocida serogroup D. Vet Immunol Immunopathol 1992;33:155–62. [187] Pati US, Srivastava SK, Roy SC, More T. Immunogenicity of outer membrane protein of Pasteurella multocida in buffalo calves. Vet Microbiol 1996;52:301–11. [188] Confer AW, Nutt SH, Dabo SM, Panciera RJ, Murphy GL. Antibody responses of cattle to outer membrane proteins of Pasteurella multocida A:3. Am J Vet Res 1996;57:1453–7. [189] Gatto NT, Dabo SM, Hancock RE, Confer AW. Characterization of, and immune responses of mice to, the purified OmpA-equivalent outer membrane protein of Pasteurella multocida serotype A:3 (Omp28). Vet Microbiol 2002;87:221–35. [190] Batra M, Pruthi AK, Virmani N, Kamil SA. Immune responses in layer chickens vaccinated with outer membrane proteins of Pasteurella multocida A:1. Indian Vet J 2011;88:17–9. [191] Basagoudanavar SH, Singh DK, Varshney BC. Immunization with outer membrane proteins of Pasteurella multocida (6:B) provides protection in mice. J Vet Med A Physiol Pathol Clin Med 2006;53:524–30. [192] Kharb S, Charan S. Mucosal immunization provides better protection than subcutaneous immunization against Pasteurella multocida (B:2) in mice preimmunized with the outer membrane proteins. Vet Res Commun 2011;35:457–61. [193] Donachie W, inventor. Vaccine against Pasteurella. United States patent US 5,587,166 [1996 December 24]. [194] Confer AW, Suckow MA, Montelongo M, Dabo SM, Miloscio LJ, Gillespie AJ, et al. Intranasal vaccination of rabbits with Pasteurella multocida A:3 outer membranes that express iron-regulated proteins. Am J Vet Res 2001;62:697–703. [195] Gunawardana GA, Frost AJ, Wilkie I. Evaluation of the immune response and efficacy in chickens of vaccines prepared from P. multocida capsular type A grown in iron-depleted conditions. Br Poult Sci 2004;45(Suppl. 1):S18–9. [196] Borkowska-Opacka B, Kedrak A. Evaluation of immunogenicity of outer membrane proteins of Pasteurella multocida serotype B:2,5 in cattle. Bull Vet Inst Pulawy 2003;47:377–85. [197] Kedrak A, Borkowska-Opacka B. Immunological response to outer membrane proteins of Pasteurella multocida serotype A:3 in calves. Bull Vet Inst Pulawy 2003;47:387–94. [198] Prado ME, Dabo SM, Confer AW. Immunogenicity of iron-regulated outer membrane proteins of Pasteurella multocida A:3 in cattle: molecular characterization of the immunodominant heme acquisition system receptor (HasR) protein. Vet Microbiol 2005;105:269–80. [199] Kumar B, Chaturvedi VK, Somrajan SR, Kumar P, Sreedevi R, Kumar S, et al. Comparative immune response of purified native OmpH protein derived from Pasteurella multocida P52 and oil adjuvant vaccine against hemorrhagic septicemia in mice. Indian J Anim Sci 2011;81:1193–6. [200] Confer AW, Ayalew S. The OmpA family of proteins: roles in bacterial pathogenesis and immunity. Vet Microbiol 2013;163:207–22. [201] Ali HA, Sawada T, Noda K. Protectivity of an immunoaffinity-purified 39 kDa capsular protein of avian Pasteurella multocida in mice. J Vet Med Sci 2004;66:1603–4. [202] Borrathybay E, Peng Q, Yan F, He C, Nazierbieke W. Cross-protective effect of the Cp39 adhesive proteins against avian Pasteurella multicida in mice. Acta Microbiol Sin 2010;50:360–6. [203] Emery DA, Straub DE, Huisinga R, Carlson BA, inventor. Active immunization using a siderophore receptor protein. United States patent US 6432412 [2000 February 22]. [204] Chang PC, Wu JR, Shien JH, Shieh HK, inventor. Subunit vaccine of Pasteurella multocida in veterinary uses. United States patent US 8084043 B2 [2011 December 27]. [205] Chomnawang MT, Nabnuengsap J, Kittiworakarn J, Pathanasophon P. Expression and immunoprotective property of a 39-kDa PlpB protein of Pasteurella multocida. J Vet Med Sci 2009;71:1479–85. [206] Hatfaludi T, Al-Hasani K, Gong L, Boyce JD, Ford M, Wilkie IW, et al. Screening of 71 P. multocida proteins for protective efficacy in a fowl cholera infection model and characterization of the protective antigen PlpE. PLoS ONE 2012;7:e39973. [207] Brown J, Dawe DL, Davis RB, Foster JW, Srivastava KK. Fowl cholera immunization in turkeys. I. Efficacy of various cell fractions of Pasteurella multocida as vaccines. Appl Microbiol 1970;19:837–41. [208] Uchida C, Kimura Y, Kubota S, Sasaki O. Protective effect of Pasteurella multocida cell-free antigen and toxoid against challenge with toxigenic strains of Pasteurella multocida in mice. J Vet Med Sci 2003;65:737–40. [209] Jarvinen LZ, Hogenesch H, Suckow MA, Bowersock TL. Induction of protective immunity in rabbits by coadministration of inactivated Pasteurella multocida toxin and potassium thiocyanate extract. Infect Immun 1998;66:3788–95. [210] Jarvinen LZ, HogenEsch H, Suckow MA, Bowersock TL. Intranasal vaccination of new zealand white rabbits against pasteurellosis, using

[211] [212] [213] [214]




[218] [219]



[222] [223]

[224] [225]















alginate-encapsulated Pasteurella multocida toxin and potassium thiocyanate extract. Comp Med 2000;50:263–9. Cameron CM, Smit G. Immune response of rabbits, mice and sheep to polyvalent Pasteurella vaccine. Onderstepoort J Vet 1970;37:217–23. Cameron CM, Bester FJ. The inefficacy of polivalent Pasteurella multocida vaccines for sheep. Onderstepoort J Vet 1983;50:101–4. Cameron CM, Bester FJ. Formulation of an effective Pasteurella multocida vaccine for sheep. Onderstepoort J Vet 1984;51:189–91. Bording A, Nymark K, Smidt E. Field trials with a new genetically engineered vaccine for protection against progressive atrophic rhinitis in pigs. Acta Vet Scand 1994;35:155–63. Liao CM, Huang C, Hsuan SL, Chen ZW, Lee WC, Liu CI, et al. Immunogenicity and efficacy of three recombinant subunit Pasteurella multocida toxin vaccines against progressive atrophic rhinitis in pigs. Vaccine 2006;24:27–35. Tang X, Wu B, Zhao Z, Deng Y, He H, He Q, et al. Characteristics and immunogenicity of the N-terminal and C-terminal recombinants of Pasteurella multocida toxin. Wei Sheng Wu Xue Bao 2008;48:213–9 [in Chinese]. Seo J, Pyo H, Lee S, Lee J, Kim T. Expression of 4 truncated fragments of Pasteurella multocida toxin and their immunogenicity. Can J Vet Res 2009;73:184–9. Lee J, Woo HJ. Antigenicity of partial fragments of recombinant Pasteurella multocida toxin. J Microbiol Biotechnol 2010;20:1756–63. Hsuan SL, Liao CM, Huang C, Winton JR, Chen ZW, Lee WC, et al. Efficacy of a novel Pasteurella multocida vaccine against progressive atrophic rhinitis of swine. Vaccine 2009;27:2923–9. Kasten RW, Wakenell PS, Ahmad S, Yilma TD, Hirsh DC. Lack of protection against avian cholera by vaccination with recombinant P6-like protein from Pasteurella multocida. Avian Dis 1997;41:972–6. Kim YH, Cheong KY, Shin WS, Hong SY, Woo HJ, Kwon MS. Immunological characterization of full and truncated recombinant clones of OmpH(D:4) obtained from Pasteurella multocida (D:4) in Korea. J Microbiol Biotechnol 2006;16:1529–36. Lee J. Immunogenicity of recombinant outer membrane protein H from Pasteurella multocida. Korean J Microbiol Biotechnol 2006;34:273–7. Kwon M, Kim YB, Leel J. Protective antibodies and immunity elicited by immunization with outer membrane protein H of Pasteurella multocida in mice. Korean J Microbiol 2007;43:7–13. Lee J, Kim YB, Kwon M. Outer membrane protein H for protective immunity against Pasteurella multocida. J Microbiol 2007;45:179–84. Dabo SM, Confer A, Montelongo M, York P, Wyckoff 3rd JH. Vaccination with Pasteurella multocida recombinant OmpA induces strong but nonprotective and deleterious Th2-type immune response in mice. Vaccine 2008;26:4345–51. Jeong K, Maeng K, Song J, Hong S, Chung T, Kwon M. Construction of genetically modified tobacco (Nicotiana tabacum cv. Petit havana) harboring ompH(A:3) from Pasteurella multocida (A:3). Biotechnol Bioprocess Eng 2008;13: 115–21. Sthitmatee N, Numee S, Kawamoto E, Sasaki H, Yamashita K, Takahashi N, et al. Protection of chickens from fowl cholera by vaccination with recombinant adhesive protein of Pasteurella multocida. Vaccine 2008;26:2398–407. Tatum FM, Tabatabai LB, Briggs RE. Protection against fowl cholera conferred by vaccination with recombinant Pasteurella multocida filamentous hemagglutinin peptides. Avian Dis 2009;53:169–74. Tatum FM, Tabatabai LB, Briggs RE. Cross-protection against fowl cholera disease with the use of recombinant Pasteurella multocida FHAB2 peptides vaccine. Avian Dis 2012;56:589–91. Yasin ISM, Yusoff SM, Mohd ZS, Mohd EAW. Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats. Trop Anim Health Prod 2011;43:179–87. Wu JR, Shien JH, Shieh HK, Chen CF, Chang PC. Protective immunity conferred by recombinant Pasteurella multocida lipoprotein E (PlpE). Vaccine 2007;25:4140–8. Okay S, Ozcengiz E, Gursel I, Ozcengiz G. Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice. Res Vet Sci 2012;93:1261–5. Hussaini J, Nazmul MHM, Abdullah MA, Ismail S. Recombinant clone ABA392 protects laboratory animals from Pasteurella multocida serotype B. Afr J Microbiol Res 2011;5:2596–9. Hussaini J, Abdullah MA, Ismail S. Expression and immunogenicity determination of recombinant rlone of Pasteurella multocida serotype B against haemorrhagic septicaemia: towards a vaccine development. J Anim Vet Adv 2012;11:351–6. Register KB, Sacco RE, Brockmeier SL. Immune response in mice and swine to DNA vaccines derived from the Pasteurella multocida toxin gene. Vaccine 2007;25:6118–28. Singh S, Singh VP, Cheema PS, Sandey M, Ranjan R, Kumargupta S, et al. Immune response to dna vaccine expressing transferrin binding protein a gene of Pasteurella multocida. Braz J Microbiol 2011;42:750–60. Gong Q, Cheng M, Niu M. Out membrane protein DNA vaccines for protective immunity against virulent avian Pasteurella multocida in chickens. Proc Environ Sci 2011;8:723–9. Gong Q, Qu N, Niu M, Qin C, Cheng M, Sun X, et al. Immune responses and protective efficacy of a novel DNA vaccine encoding outer membrane protein of avian Pasteurella multocida. Vet Immunol Immunopathol 2013;152: 317–24.